PolyPid (PYPD) Investor presentation summary

Company overview and technology

• Focuses on improving patient outcomes through innovative biopharmaceutical solutions.

• Core KynatrixTM technology enables long-acting, controlled, and customizable drug release.

• Holds 176 granted and pending patents, with operations in Israel and the U.S.

• Operates a GMP-certified, 18,000 sq ft commercial-ready facility.

Lead product and clinical results

• D-PLEX 100 is a high-concentration doxycycline formulation for local delivery over 30 days.

• Indicated for prevention of surgical site infections (SSIs) in abdominal colorectal surgery.

• Achieved 60% reduction in SSI in Phase 3 trial, with significant reductions in related endpoints.

• Received Breakthrough Therapy, Fast Track, and QIDP designations.

Market opportunity and adoption

• Addresses a US total addressable market of 12M inpatient surgical procedures annually, with 4.4M abdominal surgeries.

• SSI costs average $30K per patient, with additional penalties and reputational risks for hospitals.

• D-PLEX 100 eligible for NTAP program, offering up to 75% reimbursement.

• Surgeons and pharmacy directors show high likelihood of adoption and formulary coverage.